Product Details
Ozempic
Semaglutide1.34 mg/mL
Solution for Injection
3-mL Prefilled Pen
DIN/PIN/NPN
02471469
Manufacturer
Novo Nordisk Canada Inc.
Formulary Listing Date
2019-09-30
Unit Price
218.0300
Amount MOH Pays
218.0300
Coverage Status
Limited Use Product Insulin or Oral Hypoglycemic Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
A10BJ06
Interchangeable Products
NOLU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 665 | Indefinite | For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate. Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor. Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format. Reimbursed dose: As per the product monograph |